159 related articles for article (PubMed ID: 15519508)
1. Thalidomide in solid tumours: the resurrection of an old drug.
Sleijfer S; Kruit WH; Stoter G
Eur J Cancer; 2004 Nov; 40(16):2377-82. PubMed ID: 15519508
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.
Ribatti D; Vacca A
Leukemia; 2005 Sep; 19(9):1525-31. PubMed ID: 15973447
[TBL] [Abstract][Full Text] [Related]
3. Thalidomid: current role in the treatment of non-plasma cell malignancies.
Kumar S; Witzig TE; Rajkumar SV
J Clin Oncol; 2004 Jun; 22(12):2477-88. PubMed ID: 15197211
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide: from teratogen to anti-angiogenic.
Grover JK; Vats K
Indian J Cancer; 2001 Mar; 38(1):22-32. PubMed ID: 14758882
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide: when everything old is new again.
Nirenberg A
Clin J Oncol Nurs; 2001; 5(1):15-8. PubMed ID: 11899395
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide: mechanisms of action.
Paravar T; Lee DJ
Int Rev Immunol; 2008; 27(3):111-35. PubMed ID: 18437602
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
[No Abstract] [Full Text] [Related]
9. [Thalidomide--new prospective therapy in oncology].
Pałgan K; Pałgan I
Wiad Lek; 2003; 56(9-10):455-9. PubMed ID: 15049211
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide in solid malignancies.
Eisen T
J Clin Oncol; 2002 Jun; 20(11):2607-9. PubMed ID: 12039920
[No Abstract] [Full Text] [Related]
11. [The revival of thalidomide: an old drug with new indications].
Laffitte E
Rev Prat; 2006 Nov; 56(18):1977-83. PubMed ID: 17274497
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide in small cell lung cancer: wrong drug or wrong disease?
Rüegg C; Peters S
J Natl Cancer Inst; 2009 Aug; 101(15):1034-5. PubMed ID: 19608998
[No Abstract] [Full Text] [Related]
13. [Using thalidomide against pathological neovascularization].
Eisenkraft A; Luria S; Robenshtok E; Hourvitz A
Harefuah; 2003 Mar; 142(3):212-6, 237. PubMed ID: 12696477
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide: present and future in multiple myeloma.
Hussein MA
Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
[TBL] [Abstract][Full Text] [Related]
15. [Angiogenesis and lung cancer].
Pérol M; Arpin D
Bull Cancer; 2007 Jul; 94 Spec No():S220-31. PubMed ID: 17846008
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies.
Gilheeney SW; Lyden DC; Sgouros S; Antunes N; Gerald W; Kramer K; Lis E; Meyers P; Rosen N; Thaler HT; Trippett T; Wexler L; Dunkel IJ
Pediatr Blood Cancer; 2007 Sep; 49(3):261-5. PubMed ID: 16972243
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.
Abidi MH; Tove I; Ibrahim RB; Maria D; Peres E
Am J Hematol; 2007 Oct; 82(10):932-3. PubMed ID: 17617785
[TBL] [Abstract][Full Text] [Related]
18. Individualizing treatment of patients with myeloma in the era of novel agents.
San-Miguel J; Harousseau JL; Joshua D; Anderson KC
J Clin Oncol; 2008 Jun; 26(16):2761-6. PubMed ID: 18427148
[TBL] [Abstract][Full Text] [Related]
19. Clinical translation of angiogenesis inhibitors.
Kerbel R; Folkman J
Nat Rev Cancer; 2002 Oct; 2(10):727-39. PubMed ID: 12360276
[TBL] [Abstract][Full Text] [Related]
20. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms.
Baumann M; Krause M; Dikomey E; Dittmann K; Dörr W; Kasten-Pisula U; Rodemann HP
Radiother Oncol; 2007 Jun; 83(3):238-48. PubMed ID: 17502118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
